Novo Nordisk rejoined the ABPI after a two-year suspension linked to promotional concerns. Audits confirmed compliance with ...

I cringe when I see people doing the buccal fat removal surgery,” says one A-list esthetician. Here’s what you can do instead ...

Both the total and core versions are up only about 2% over the past year. More impressive, however, is that the PPI Finished ...

As evident, Hazlitt’s one lesson has vast applications. This essay now delves into its deployment on the Danish welfare state ...

Hims & Hers is shifting towards personalized medicine with AI-backed solutions. Find out why HIMS stock is buyable despite ...

Two years after she was accused of sexual harassment by three former back-up dancers, Lizzo is launching her musical comeback ...

The FDA wants bulk production of copycat versions of popular weight-loss drugs to stop, but telehealth companies and compounding pharmacies ...

Ozempic (semaglutide) commonly causes constipation and other digestive side effects. Certain diet and lifestyle changes can often help manage mild constipation, but you may need medical care if it ...

Novo Nordisk released clinical trial results on Monday for its potential Ozempic successor, but for the second time, it fell short of analysts’ expectations, disappointing Wall Street.

Novo Nordisk shares gained Monday as the company said it would present new data on the ability of semaglutide, the active ingredient in its weight-loss drugs Ozempic and Wegovy, to lower heart risks.